Cyltezo (adalimumab-adbm) — FDA-Approved Biosimilar to Humira (adalimumab)

TNF-alpha Inhibitor Biosimilar · Approved 2017 · $0–$35/mo for most insured patients

🔬 What Is Cyltezo?

Cyltezo (adalimumab-adbm) is an FDA-approved biosimilar to Humira (adalimumab). A biosimilar is a biological medication that is highly similar to an already-approved reference biologic, with no clinically meaningful differences in safety, purity, or potency. Cyltezo (adalimumab-adbm) holds FDA interchangeable biosimilar status for Humira — meaning pharmacists can substitute it without prescriber intervention in states that permit it. It is the only adalimumab biosimilar with full interchangeable designation for all Humira indications.

🛒 Order Cyltezo — Direct from BiologicHealthPlus

Our pharmacist team will contact you within 2 hours to verify your prescription and insurance.

With Insurance

$0–$35/mo for most insured patients

Boehringer Ingelheim Cares

Uninsured / PAP

Free

Income-based assistance

Start My Order → 💬 WhatsApp 📞 Call

Cyltezo Overview

Property	Details
Brand Name	Cyltezo
Generic Name	adalimumab-adbm
Reference Biologic	Humira (adalimumab)
Manufacturer	Boehringer Ingelheim
Drug Class	TNF-alpha Inhibitor Biosimilar
FDA Approval	2017
Route	Subcutaneous injection
Approved Conditions	Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease, Ulcerative Colitis, HS, Uveitis, JIA
Copay Program	Boehringer Ingelheim Cares — $0–$35/mo for most insured patients

Approved Conditions

✓Rheumatoid Arthritis✓Psoriatic Arthritis✓Ankylosing Spondylitis✓Plaque Psoriasis✓Crohn's Disease✓Ulcerative Colitis✓HS ✓Uveitis✓JIA

Cyltezo vs Humira (adalimumab)

Cyltezo has been demonstrated to be biosimilar to Humira (adalimumab) through comprehensive analytical, non-clinical, and clinical studies. The FDA requires that biosimilars have no clinically meaningful differences from the reference product. Patients who are stable on Humira (adalimumab) should discuss any potential switch to Cyltezo with their prescriber.

Factor	Cyltezo	Humira (adalimumab)
FDA Status	Biosimilar (approved 2017)	Reference biologic
Active Ingredient	adalimumab-adbm	adalimumab
Mechanism	TNF-alpha Inhibitor	Same
Approved Indications	Same as Humira (adalimumab)	Multiple FDA-approved
Typical Patient Cost	$0–$35/mo for most insured patients	$0–$35/mo (varies by plan)

Yes. The FDA requires biosimilars to demonstrate there are no clinically meaningful differences in safety, purity, and potency compared to the reference product. Cyltezo underwent rigorous clinical studies demonstrating biosimilarity to Humira (adalimumab). Your prescriber can discuss whether Cyltezo is appropriate for your specific situation.

Many patients do switch from reference biologics to biosimilars. The decision should be made in consultation with your prescriber. Switching is generally safe for stable patients, but your doctor may want to monitor you during the transition. BiologicHealthPlus can coordinate the prior authorization for Cyltezo and ensure a seamless supply transition.

Most commercial insurance plans and Medicare Part D cover Cyltezo with prior authorization. In many cases, Cyltezo may have a lower tier placement on formularies than Humira (adalimumab), potentially reducing your copay. BiologicHealthPlus verifies your insurance coverage, handles all prior authorization, and enrolls you in the Boehringer Ingelheim Cares copay program to minimize your out-of-pocket costs.

Without insurance, Cyltezo costs approximately $1150/month at list price — lower than Humira (adalimumab)'s list price. Uninsured or underinsured patients may qualify for patient assistance through Boehringer Ingelheim Cares. BiologicHealthPlus will find every available savings option for you at no charge.

📚 Sources & Further Reading

🔗

FDA Biosimilar ApprovalsFDA

🔗

BiosimilarWikipedia

🔗

ACR Biosimilar PositionACR

🔗

Biosimilar DevelopmentNIH/NCBI

🔗

Medicare Biosimilar CoverageCMS

Medical Disclaimer: Educational content reviewed by BiologicHealthPlus Clinical Team. Last reviewed: August 2026.

Medical Disclaimer: This page is for informational purposes only. Cyltezo requires a valid prescription. Consult your physician before making any changes to your medication. Last updated: August 2026.